首页> 外文OA文献 >PMS21 MIXED TREATMENT COMPARISONS: AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

【2h】

PMS21 MIXED TREATMENT COMPARISONS: AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

机译：PMS21混合疗法比较：在风湿性关节炎治疗中一种或多种TNF抑制剂治疗失败后，利妥昔单抗（MABTHERA®）的循证预算影响模型

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Launois R; Riou França L; Maunoury F; Boissier MC; Florentin V;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. [J] . Launois R, Payet S, Saidenberg-Kermanach N, Joint, bone, spine : . 2008,第6期

机译：一种或多种TNFα抑制剂治疗类风湿关节炎失败后，利妥昔单抗的预算影响模型。
2. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [J] . Cheryl P Ferrufino, Julie Munakata, Wenhui Wei, ClinicoEconomics and Outcomes Research . 2018,第10期

机译：sarilumab用于治疗类风湿性关节炎的预算影响分析，这些患者对常规合成DMARD或TNF抑制剂疗法的反应不足
3. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF alpha inhibitors and rituximab [J] . Listing Joachim, Kekow Joern, Manger Bernhard, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2015,第2期

机译：类风湿关节炎的死亡率：疾病活动的影响，糖皮质激素，TNFα抑制剂和利妥昔单抗的治疗
4. Development of TNF-alpha Inhibitor Drugs in Treatment of Rheumatoid Arthritis [C] . Dong Jin-rui, He Ming-hao, Han Mo, Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：TNF-α抑制剂在类风湿关节炎治疗中的应用
5. Comparison of the Therapeutic Efficacy of Rheumatoid Arthritis Treatments [D] . Davis, Kacy. 2021

机译：类风湿性关节炎治疗治疗疗效的比较
6. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies Corrigendum [O] . 2019

机译：对传统合成DMARD或TNF抑制剂治疗反应不佳的类风湿性关节炎患者使用sarilumab的预算影响分析更正
7. PMS88 Mixed Treatment Comparison, Cost-Effectiveness Analysis and Budget Impact Model in the Treatment of Rheumatoid Arthritis After Failure of Conventional Dmard Therapy Using Comprehensive Bayesian Decision Analytical Modelling [O] . Launois R., Le Moine J.G., Huynh T.M.T. 2012

机译：使用综合贝叶斯决策分析模型的常规Dmard疗法失败后类风湿关节炎的PMS88混合治疗比较，成本效果分析和预算影响模型

PMS21 MIXED TREATMENT COMPARISONS: AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

著录项

引文网络

相似文献

相关主题

期刊订阅